A gene variation (rs12691) in the CCAT/enhancer building α modulates glucose metabolism in metabolic syndrome

Delgado-Lista , J., Perez-Martinez , P., Garcia-Rios , A., Phillips , C., Hall, W., Gjelstad, I. M. F., Lairon, D., Saris, W., Kieć- Wilk , B., Karlström , B., Drevon, C., Blaak, E. E., Dembinska-Kieć, A., Risérus , U., Lovegrove, J. ORCID: https://orcid.org/0000-0001-7633-9455, Roche, H. M. and Lopez-Miranda , J. (2013) A gene variation (rs12691) in the CCAT/enhancer building α modulates glucose metabolism in metabolic syndrome. Nutrition Metabolism and Cardiovascular Diseases, 23 (5). pp. 417-423. ISSN 0939-4753 doi: 10.1016/j.numecd.2011.09.008

Abstract/Summary

Background and aims CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients. Methods and results Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration. Conclusion The presence of the A allele of rs12691 influences glucose metabolism of MetS patients. Clinical Trials Registry number NCT00429195.